Bristol's haematology specialists manage severe aplastic anaemia and refractory ITP patients requiring higher-dose Eltrombopag therapy. Rompag 50mg provides substantial cost savings versus brand Revolade without compromising quality.
Rompag is used in combination immunosuppressive regimens for aplastic anaemia, producing complete haematologic responses in a majority of previously untreated patients per clinical trial data.
|
FAQ: Is Rompag effective if I've already tried and
failed other ITP treatments? Yes, Eltrombopag (Rompag)
is specifically positioned as a second-line option for patients who haven't
responded adequately to first-line treatments like corticosteroids or IVIG.
Many patients who don't respond to initial therapies do achieve meaningful
platelet responses with Eltrombopag, which works through a different
mechanism than immunosuppressive treatments. |
